RSS Feed
Tags
adaptive trials advertising advisory committees best practices biologics biosimilar biotech BLA cancer Cato BioVentures Cato Research CBER CDER CDRH clinical trials CMC conference DDMAC DIA drug development eCTD efficacy FDA GlobalSubmit guest post guidance IND inspections medical devices NDA NIH nonclinical research oncology outsourcing personalized medicine postmarketing protocol safety slides Social Media statistical analysis transparency venture capital warning letters webinarCategories
Archives
Links
Follow us on Twitter!
- Featured yesterday at Fierce Biotech IT - Cato lists five keys to success in adaptive trials http://bit.ly/aHry0A about 16 hours ago from TweetDeck
- RT @reuters: "Outgunned FDA tries to get tough with drug ads" http://bit.ly/btorHn 08:45:47 PM September 07, 2010 from web
- @MicroConstants Thanks for retweeting! 07:27:43 PM September 07, 2010 from TweetDeckin reply to MicroConstants
- New blog post: August 2010 FDA Guidances - http://ask-cato.com/mg 02:50:26 PM September 07, 2010 from WordTwit Plugin
Tag Archives: Cato BioVentures
Use A Detailed Development Plan to Secure Venture Capital
This is a guest post by Shane Grivna, Ph.D. Shane is a Clinical Strategy Scientist for Cato Research and an Analyst for Cato BioVentures. It’s a tough time to be asking for money. Whether you’re a highschooler who needs cash … Continue reading
Posted in Guest Posts, Venture Capital
Tagged biologics, business plan, Cato BioVentures, CDRH, development plan, drug development, FDA, venture capital
1 Comment
Approval of Therapeutic Cancer Vaccines
This is a guest post by Laura DiMichele, Ph.D., R.A.C. Laura is a Clinical Strategy Scientist at Cato Research. Last month, Dendreon was granted approval for Provenge®, the first cell based cancer vaccine for treatment of asymptomatic or minimally symptomatic metastatic … Continue reading
Posted in FDA, Guest Posts, Industry News, Publications
Tagged biomedical, cancer, Cancer Advances, cancer vaccine, Cato BioVentures, clinical benefit, clinical development, Dendreon, drug development, gastric cancer, gastrointestinal cancers, immune system, immunomodulators, Journal for Clinical Studies, monoclonal antibody therapy, pancreatic cancer, Provenge, serum-derived polyclonal treatment, targeted therapeutics, tumors
1 Comment
Cato at BIO 2010
The BIO International Convention is the largest global event for the biotechnology industry. It attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. This year’s … Continue reading
Posted in Conferences and Meetings
Tagged BIO, BIO 2010, biotech, biotechnology, Cato BioVentures, Cato Research, Chicago, CROs, Quebec
Comments Off
